tiprankstipranks
Trending News
More News >
Crispr Therapeutics AG (CRSP)
NASDAQ:CRSP

Crispr Therapeutics AG (CRSP) AI Stock Analysis

Compare
9,414 Followers

Top Page

CR

Crispr Therapeutics AG

(NASDAQ:CRSP)

Rating:60Neutral
Price Target:
$44.00
▲(6.38%Upside)
Crispr Therapeutics AG's stock score reflects significant financial challenges and valuation concerns, offset somewhat by positive technical indicators and strategic corporate events. The company's reliance on collaborations for revenue and external funding for liquidity are key risks. However, recent partnerships and shareholder approvals offer some optimism for strategic growth.
Positive Factors
Pipeline Diversification
The company's diversified pipeline and multiple partnerships provide significant optionality, supporting an Outperform rating.
Product Launch
Casgevy's launch shows an uptick with expected acceleration due to expanding ATCs network and increasing payer coverage.
Strategic Partnerships
CRSP announced a partnership with Sirius Therapeutics to develop and commercialize SRSD107, a next-generation, long-acting Factor XI siRNA for the treatment of blood clotting disorders.
Negative Factors
Market Competition
Several large pharmaceutical and biotech companies have late-stage FXI small molecules and monoclonal antibodies in development, indicating strong competition.
Price Target Reduction
Updating our model for upfront payments and disclosed deal terms marginally reduces our PT from $58 to $56.

Crispr Therapeutics AG (CRSP) vs. SPDR S&P 500 ETF (SPY)

Crispr Therapeutics AG Business Overview & Revenue Model

Company DescriptionCrispr Therapeutics AG (CRSP) is a leading biotechnology company focused on developing transformative gene-based medicines. The company leverages CRISPR/Cas9 gene-editing technology to create therapies for serious diseases, with a primary focus on genetic disorders, oncology, and regenerative medicine. Crispr Therapeutics has a robust pipeline of innovative product candidates designed to address unmet medical needs across various therapeutic areas.
How the Company Makes MoneyCrispr Therapeutics AG generates revenue primarily through collaborations and strategic partnerships with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments, and royalties on sales resulting from successful commercialization of jointly developed therapies. Additionally, Crispr Therapeutics may receive research grants and government funding to support its development of gene-editing therapies. The company also aims to commercialize its own drug candidates, which, upon regulatory approval, would provide another revenue stream in the form of product sales.

Crispr Therapeutics AG Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Analyzes income from different business areas, highlighting which segments drive growth and profitability, and where the company might be vulnerable or have opportunities for expansion.
Chart InsightsCrispr Therapeutics AG's revenue from collaborations has been highly volatile, with significant spikes in certain quarters, notably in late 2023 and early 2024, suggesting irregular but substantial partnership deals. Meanwhile, grant revenue has remained minimal and relatively stable, indicating limited reliance on this segment. The absence of earnings call commentary leaves the reasons for these fluctuations unclear, but the pattern suggests strategic partnerships are a key driver of revenue, albeit inconsistently. Investors should watch for announcements on new collaborations to gauge future revenue potential.
Data provided by:Main Street Data

Crispr Therapeutics AG Financial Statement Overview

Summary
Crispr Therapeutics AG faces significant financial challenges with negative income and cash flow metrics, underscoring operational inefficiencies and revenue generation issues. Despite a strong balance sheet with high equity and cash reserves, the company's negative free cash flow trend and reliance on external funding indicate potential liquidity challenges.
Income Statement
45
Neutral
Crispr Therapeutics AG has shown significant volatility in revenue and profit margins. The most recent annual report indicates a drastic revenue decline compared to previous years, with a sharp drop from 2021 to 2024. Gross and net profit margins have turned negative, highlighting operational challenges and high expenses relative to revenue. The TTM data shows a negative EBIT and EBITDA margin, indicating operational inefficiencies and ongoing financial struggles.
Balance Sheet
65
Positive
The company maintains a strong equity position with a high equity ratio, suggesting stability in its capital structure. While the debt-to-equity ratio is relatively low, indicating manageable leverage, the stockholders' equity has slightly declined over the years. The balance sheet reflects a solid cash position, which is crucial for a biotech firm investing in R&D, despite the negative net income.
Cash Flow
50
Neutral
Crispr Therapeutics AG exhibits a negative free cash flow trend, with operating cash flows consistently negative over recent years. This indicates potential liquidity challenges. The free cash flow to net income ratio is also negative, underscoring ongoing cash management issues. The cash flow from financing has been positive, which may provide temporary relief but signifies reliance on external funding.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
36.98M35.00M371.21M436.00K913.08M543.00K
Gross Profit
-88.65M-75.25M240.96M-109.81M895.13M-268.86M
EBIT
-474.40M-466.57M-222.54M-673.16M373.53M-354.44M
EBITDA
-455.24M-447.31M-202.70M-648.99M391.48M-345.25M
Net Income Common Stockholders
-385.66M-366.25M-153.61M-650.17M377.66M-348.87M
Balance SheetCash, Cash Equivalents and Short-Term Investments
1.86B1.90B1.69B1.82B2.38B1.69B
Total Assets
2.17B2.24B2.23B2.24B2.75B1.83B
Total Debt
219.36M223.69M238.63M244.02M225.03M61.43M
Net Debt
-15.83M-74.56M-150.84M32.14M-698.00M-1.11B
Total Liabilities
336.94M309.95M346.77M367.58M352.42M163.73M
Stockholders Equity
1.83B1.93B1.88B1.88B2.40B1.66B
Cash FlowFree Cash Flow
-307.86M-144.68M-272.35M-532.93M457.27M-256.72M
Operating Cash Flow
-306.47M-142.77M-260.38M-495.74M538.97M-238.37M
Investing Cash Flow
-202.44M-280.48M374.65M-258.65M-1.04B-541.17M
Financing Cash Flow
36.64M331.98M62.66M38.59M250.94M1.02B

Crispr Therapeutics AG Technical Analysis

Technical Analysis Sentiment
Positive
Last Price41.36
Price Trends
50DMA
37.51
Positive
100DMA
40.00
Positive
200DMA
43.18
Negative
Market Momentum
MACD
1.16
Negative
RSI
60.20
Neutral
STOCH
59.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRSP, the sentiment is Positive. The current price of 41.36 is above the 20-day moving average (MA) of 38.93, above the 50-day MA of 37.51, and below the 200-day MA of 43.18, indicating a neutral trend. The MACD of 1.16 indicates Negative momentum. The RSI at 60.20 is Neutral, neither overbought nor oversold. The STOCH value of 59.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CRSP.

Crispr Therapeutics AG Risk Analysis

Crispr Therapeutics AG disclosed 85 risk factors in its most recent earnings report. Crispr Therapeutics AG reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Crispr Therapeutics AG Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
$2.02B12.7124.71%20.62%14.08%
60
Neutral
$3.59B-19.71%-86.13%-67.29%
58
Neutral
$563.39M-34.26%271.44%26.65%
54
Neutral
$5.41B3.27-45.10%3.29%16.81%0.02%
52
Neutral
$866.99M-57.92%-13.37%2.57%
52
Neutral
$1.61B-70.58%100.03%64.22%
45
Neutral
$1.80B-38.04%-82.38%-164.76%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CRSP
Crispr Therapeutics AG
41.36
-22.20
-34.93%
NTLA
Intellia Therapeutics
8.31
-16.84
-66.96%
ARQT
Arcutis Biotherapeutics
13.43
4.80
55.62%
BEAM
Beam Therapeutics
17.06
-7.81
-31.40%
HRMY
Harmony Biosciences Holdings
32.97
3.92
13.49%
VERV
Verve Therapeutics
6.16
0.74
13.65%

Crispr Therapeutics AG Corporate Events

Shareholder MeetingsBusiness Operations and Strategy
CRISPR Therapeutics AG Shareholders Approve Key Proposals
Positive
Jun 9, 2025

On June 5, 2025, CRISPR Therapeutics AG held its Annual General Meeting where shareholders approved several key proposals, including amendments to the company’s Articles of Association, financial statements for 2024, and the re-election of board members and auditors. These decisions, effective upon registration, are expected to strengthen the company’s governance and operational framework, potentially enhancing its strategic positioning in the biotechnology sector.

The most recent analyst rating on (CRSP) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and Strategy
Crispr Therapeutics AG Partners with Sirius on siRNA Tech
Positive
May 19, 2025

On May 19, 2025, CRISPR Therapeutics AG announced a collaboration agreement with Sirius Therapeutics to co-develop and commercialize siRNA technology targeting Factor XI, with an upfront consideration of $95 million. The agreement includes the development of SRSD107, a next-generation siRNA designed to inhibit coagulation factor XI, showing promising results in Phase 1 trials with potential applications in various thrombotic conditions. The collaboration aims to leverage SRSD107’s potential to reduce thrombotic events while minimizing bleeding risks, positioning it as a differentiated therapy in the market.

The most recent analyst rating on (CRSP) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.

Executive/Board ChangesBusiness Operations and Strategy
CRISPR Therapeutics COO Julianne Bruno Resigns
Neutral
Mar 26, 2025

On March 24, 2025, Julianne Bruno, the Chief Operating Officer of CRISPR Therapeutics, announced her resignation effective April 11, 2025, to pursue external opportunities. Her departure is not due to any disagreement with the company. Bruno has been a key figure in advancing the company’s hematology and oncology programs and other initiatives. Her resignation marks a significant transition for CRISPR Therapeutics, which continues to strengthen its position in the biopharmaceutical industry through strategic partnerships and innovative gene-editing solutions.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.